Cancer Crossover Research (46)
46 papers in the Cancer Crossover topic, indexed by PF-Atlas from PubMed and global journals.
Cross-disease research. These studies are from related fibrotic, oncologic or regenerative fields and are tracked for mechanistic relevance to IPF. They are not direct evidence for treating idiopathic pulmonary fibrosis.
- A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy · Cell · 2026
- Nrf2-mediated metabolic reprogramming drives regulatory T cell accumulation in hepatocellular carcinoma. · Nature communications · 2026
- IL-15 Superagonists for Reprogramming the Immunosuppressive Microenvironment in Gastrointestinal Adenocarcinomas. · Cancer letters · 2026
- Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction-associated steatohepatitis. · Science translational medicine · 2026
- CAR-T cells targeting fibroblast activation protein eliminate pathological fibroblasts and preserve cardiac function in a Duchenne Muscular Dystrophy murine model. · Stem cell research & therapy · 2026
- Development of CAR Exosomes Targeting FAP for the Treatment of Intrauterine Adhesion. · Journal of extracellular vesicles · 2026
- CAR-T cells targeting activated hepatic stellate cells ameliorate liver fibrosis in mouse models. · JHEP reports : innovation in hepatology · 2026
- Intrapericardial delivery of FAP-CAR-T cells via a ROS-responsive hydrogel to treat cardiac fibrosis. · Journal of controlled release : official journal of the Controlled Release Society · 2026
- CAR-T cells generated in vivo for the targeted treatment of myocardial fibrosis. · International immunopharmacology · 2026
- Tumor-specific mechanisms and therapeutic strategies for overcoming immunotherapy resistance in advanced urological tumors. · Journal of advanced research · 2026
- From Antibody Drugs to RNA Interference and Nanotherapy: The Evolution and Integration of Targeted Strategies in Gastric Cancer. · International journal of nanomedicine · 2026
- Therapy-imprinted fibroblast memory in cholangiocarcinoma: rewiring CAF niches for immune evasion and treatment-resistant relapse. · Frontiers in immunology · 2026
- CAR T cell therapy beyond cancer: current status, challenges and future prospects. · Signal transduction and targeted therapy · 2026
- Targeting Fibroblast Activation Protein for Precision Medicine. · Accounts of chemical research · 2026
- Prospects of Chimeric Antigen Receptor T-Cell Therapy in Myelofibrosis: From Immunopathogenesis to Therapeutic Strategies. · Cancers · 2026
- Targeting fibroblast activation protein-α to treat renal fibrosis. · Cellular & molecular biology letters · 2026
- CAR T cell therapy for fighting IPF: perspectives on a living drug. · Frontiers in immunology · 2026
- Engineered T cell therapy for the treatment of cardiac fibrosis during chronic phase of myocarditis. · Theranostics · 2026
- All-trans retinoic acid and lansoprazole potentiated NKG2D-CAR T for breast cancer treatment. · International immunopharmacology · 2026
- The poly- hydrogel carrying AAV8-sTβRII alleviates scar formation in mice skin wound healing by inhibiting fibrosis. · Gene therapy · 2026
- In vivo anti-FAP CAR T therapy reduces fibrosis and restores liver homeostasis in metabolic dysfunction-associated steatohepatitis. · bioRxiv : the preprint server for biology · 2025
- The Potential of CAR-T cells for Treating Heart Diseases: Current Status and Hurdles in Clinical Translation. · The Tohoku journal of experimental medicine · 2025
- Fibroblast Activation Protein-Targeted CAR-T Cells Induce Apoptosis in Murine Cardiac Myofibroblasts. · Cardiovascular therapeutics · 2025
- Unveiling purine metabolism dysregulation orchestrated immunosuppression in advanced pancreatic cancer and concentrating on the central role of NT5E. · Frontiers in immunology · 2025
- Targeting fibroblast activation protein with chimeric antigen receptor macrophages. · Biochemical pharmacology · 2024
- CAR-T cell therapeutic avenue for fighting cardiac fibrosis: Roadblocks and perspectives. · Cell biochemistry and function · 2024
- Inflammatory Mesenteric Disease and Sarcoidosis-like Reaction in a Patient with Lung Adenocarcinoma Who Received Pembrolizumab: Paraneoplastic Syndrome, Secondary to Checkpoint Inhibitor or Chance Finding? · Current oncology (Toronto, Ont.) · 2024
- Keep It Moving: Physical Activity in the Prevention of Obesity-Driven Pancreatic Cancer. · Cancer research · 2024
- Integrating mTOR Inhibition and Photodynamic Therapy Based on Carrier-Free Nanodrugs for Breast Cancer Immunotherapy. · Advanced healthcare materials · 2024
- Disruption of Super-Enhancers in Activated Pancreatic Stellate Cells Facilitates Chemotherapy and Immunotherapy in Pancreatic Cancer. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
- Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti-PD-1 Immunotherapy in Fibrotic Tumors. · Cancer research · 2023
- Oxygen microcapsules improve immune checkpoint blockade by ameliorating hypoxia condition in pancreatic ductal adenocarcinoma. · Bioactive materials · 2023
- The mechanism and application of traditional Chinese medicine extracts in the treatment of lung cancer and other lung-related diseases. · Frontiers in pharmacology · 2023
- Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals RNA N6-methyladenosine modification associated with prognosis and drug resistance in acute myeloid leukemia. · Frontiers in immunology · 2023
- Strategy of targeting the tumor microenvironment via inhibition of fibroblast/fibrosis remodeling new era to cancer chemo-immunotherapy resistance. · European journal of pharmacology · 2023
- Multifunctional Liposomes Remodeling Tumor Immune Microenvironment for Tumor Chemoimmunotherapy. · Small methods · 2023
- Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. · Nature communications · 2023
- Research advance in lipid nanoparticle-mRNA delivery system and its application in CAR-T cell therapy. · Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2022
- Tannins in Terminalia bellirica inhibits hepatocellular carcinoma growth via re-educating tumor-associated macrophages and restoring CD8 T cell function. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022
- TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer. · Journal for immunotherapy of cancer · 2022
- Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment. · Frontiers in cell and developmental biology · 2022
- Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment. · Gastroenterology · 2022
- Lung Cancer Surgery after Treatment with Anti-PD1/PD-L1 Immunotherapy for Non-Small-Cell Lung Cancer: A Case-Cohort Study. · Cancers · 2021
- Nivolumab and anti-HCV activity, a case report. · Acta clinica Belgica · 2021
- Renin-Angiotensin System in the Tumor Microenvironment. · Advances in experimental medicine and biology · 2020
- [Can nivolumab be used safely in idiopathic pulmonary fibrosis?]. · Revue des maladies respiratoires · 2019
Medical disclaimer. Research listings are for information only and are not medical advice.